PROSTATE CANCER (PC) The Prostate Cancer (PC) Program aims to advance scientific knowledge that will reduce the morbidity and mortality attributed to PC and lead to improvements in patients? quality of life. The PC Program has three primary aims: (1) Develop approaches for determining early stage PC risk, optimizing detection strategies, and deploying risk-based interventions; (2) Advance the molecular understanding of the androgen receptor signaling program to inform the rational design of therapeutic strategies for treating high-risk localized and metastatic PC; and (3) Evolve therapeutic approaches for the treatment of PCs directed toward inhibiting key oncogenic (intrinsic) drivers and modulating components of the tumor microenvironment. The PC Program has 42 members based at the University of Washington (UW) or Fred Hutch (FH), with clinical practice sites at the UW, Seattle Cancer Care Alliance (SCCA), and Veterans Administration (VA) Puget Sound Health Care System. Nine PC members have primary appointments at FH and 33 members at UW spanning 11 Departments and Divisions. Ten members joined this program since the last cycle. The current research portfolio of PC members is $11.6M (direct costs), of which $8.6M is peer-reviewed funding, including $2M from the NCI. A substantial component of the research funding is in the form of P50, P01, U54 and other collaborative grants. The Prostate Cancer program members published a total of 558 papers in the current grant period, of which 31% were intra-programmatic, 22% were inter-programmatic, and 56% had external co-authors. Eleven out of 12 Consortium Shared Resources were utilized by PC members in the course of their work. In addition to providing key shared resources, in particular Comparative Medicine, Genomics & Bioinformatics, and Research Pathology Shared Resources, the P30 CCSG supports this research program by providing administrative and logistical support for PC Program meetings; pilot funding for new research projects; and recruitment of new faculty.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015704-45
Application #
9853664
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Herman, Daniel S; Smith, Christina; Liu, Chang et al. (2018) Efficient Detection of Copy Number Mutations in PMS2 Exons with a Close Homolog. J Mol Diagn 20:512-521
Birnbaum, Jeanette K; Duggan, Catherine; Anderson, Benjamin O et al. (2018) Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries: a modelling study. Lancet Glob Health 6:e885-e893
Partridge, Emma K; Neuhouser, Marian L; Breymeyer, Kara et al. (2018) Comparison of Nutrient Estimates Based on Food Volume versus Weight: Implications for Dietary Assessment Methods. Nutrients 10:
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437
Kuzma, Jessica N; Cromer, Gail; Hagman, Derek K et al. (2018) Consuming glucose-sweetened, not fructose-sweetened, beverages increases fasting insulin in healthy humans. Eur J Clin Nutr :
Neumeyer, Sonja; Banbury, Barbara L; Arndt, Volker et al. (2018) Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer. Br J Cancer 118:1639-1647
Puré, Ellen; Hingorani, Sunil R (2018) Mesenchymal Cell Plasticity and Perfidy in Epithelial Malignancy. Trends Cancer 4:273-277
Yu, Hsiang; Cheng, Yu-Jen; Wang, Ching-Yun (2018) Methods for multivariate recurrent event data with measurement error and informative censoring. Biometrics 74:966-976
Linden, Hannah M; Peterson, Lanell M; Fowler, Amy M (2018) Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clin 13:415-422
Barault, Ludovic; Amatu, Alessio; Siravegna, Giulia et al. (2018) Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut 67:1995-2005

Showing the most recent 10 out of 1267 publications